Clinical outcome of an early psychosis intervention program: Evaluation in a real-world context

Australian and New Zealand Journal of Psychiatry

Volumn 38, Issue 9, 2004, Pages 694-701

  Nash, Louise ^a   Gorrell, Joanne ^b   Cornish, Alison ^b   Rosen, Alan ^b   Miller, Vivienne ^c   Tennant, Chris ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c The Mental Health Service Conference   (Australia)

Author keywords

Adolescent and adult; Early psychosis; Psychotic disorders; Treatment outcome

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; COGNITIVE THERAPY; CONTINUING EDUCATION; CONTROLLED STUDY; EXPERIENCE; FAMILY THERAPY; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MENTAL HEALTH SERVICE; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; PSYCHOSOCIAL CARE; RATING SCALE; RESOURCE MANAGEMENT; SCORING SYSTEM; STAFF TRAINING; SYMPTOM; TREATMENT OUTCOME; WORKSHOP;

ADULT; AUSTRALIA; BRIEF PSYCHIATRIC RATING SCALE; EARLY DIAGNOSIS; EPISODE OF CARE; FEMALE; HEALTH PERSONNEL; HUMANS; MALE; MENTAL HEALTH SERVICES; OUTCOME ASSESSMENT (HEALTH CARE); PROGRAM DEVELOPMENT; PROGRAM EVALUATION; PSYCHOLOGY; PSYCHOTHERAPY; PSYCHOTIC DISORDERS; QUESTIONNAIRES; SOCIAL ENVIRONMENT; TIME FACTORS;

EID: 4544385438     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2004.01442.x     Document Type: Article

References (71)

1. Falloon IRH, Kydd RR, Coverdale JH, Laldlaw TM. Early detection and intervention for initial episodes of schizophrenia. Schizophrenia Bulletin 1996; 22:271-282.
2. McGlashan TH. Early detection and intervention in schizophrenia: research. Schizophrenia Bulletin 1996; 22:327-345.
3. Yung A, McGorry P. The prodromal phase of first-episode psychosis: past and current conceptualisations. Schizophrenia Bulletin 1996; 22:353-370.
4. McGorry P, Yung A, Phillips L et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry 2002; 59:921-928.
5. Yung A, Phillips L, McGorry P et al. Prediction of psychosis. A step towards indicated prevention of schizophrenia. [Comment]. British Journal of Psychiatry 1998; 172:14-20.
6. McGorry P, Yung A, Phillips L. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophrenia Research 2001; 5:17-29.
7. Wyatt R, Green M, Tuma A. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychological Medicine 1997; 45:174-176.
8. Beiser MED, Fleming J, Iaconc W. Establishing the onset of psychotic illness. American Journal of Psychiatry 1993; 150:1349-1354.
9. Larsen T, McGlashan T, Moe L. First-episode schizophrenia. I. Early course parameters. Schizophrenia Bulletin 1996; 22:241-256.
10. Johnstone E, Crow T, Johnson A, MacMillan J. The Northwick Park study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. British Journal of Psychiatry 1996; 148:115-120.
11. Loebal A, Lieberman J, Jose M et al. Duration of psychosis and outcome in first episode schizophrenia. American Journal of Psychiatry 1992; 149:1183-1188.
12. McGorry P, Edwards J, Mihalopoulos C, Harrigan S, Jackson H EPPIC. An evolving system of early detection and optimal management. Schizophrenia Bulletin 1996; 22:305-326.
13. Ho B-C, Andreason N, Flaum M, Nopoulos P, Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first episode schizophrenia. American Journal of Psychiatry 2000; 157:808-815.
14. Craig T, Bromet E, Fennig S, Tanenberg-Karant M, Lavelle J, Galambos N. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? American Journal of Psychiatry 2000; 157:60-66.
15. McGorry P. Evaluating the importance of reducing the duration of untreated psychosis. Australian and New Zealand Journal of Psychiatry 2000; 34: S145-S149.
16. Johannessen J, McGlashan T, Larsen T et al. Early detection strategies for untreated first-episode psychosis. Schizophrenia Research 2001; 51:39-46.
17. Norman R, Malla A. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychological Medicine 2001; 31:381-400.
18. Verdoux H, Liraud F, Bergey C, Assens F, Abalan F, van Os J. Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients. Schizophrenia Research 2001; 49:231-241.
19. Black K, Peters L, Rui Q, Milliken H, Whitehorn D, Kopala L. Duration of untreated psychosis predicts treatment outcome in an early psychosis program. Schizophrenia Research 2001; 47:215-222.
20. Malla A, Norman R, Manchanda R et al. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophrenia Research 2002; 54:231-242.
21. Kalla O, Aaltonen J, Wahl-strom J et al. Duration of untreated psychosis and its correlated in first-episode psychosis in Finland and Spain. Acta Psychiatrica Scandinavica 2002; 106:265-275.
22. May P, Dixon W, Yale C, Thiele D, Kraude W. Schizophrenia. A follow-up study of the results of five forms of treatment. Archives of General Psychiatry 1981; 38:776-784.
23. Birchwood M, McGorry P, Jackson H. Early intervention in schizophrenia. British Journal of Psychiatry 1997; 170:2-5.
24. Linszen D, Dingemans P, Lemor M. Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. Schizophrenia Research 2001; 51:55-61.
25. McGorry P. Early psychosis reform: too fast or too slow? Acta Psychiatrica Scandinavica 2002; 106:249-251.
26. Birchwood M, Todd P, Jackson C. Early intervention in psychosis: The critical-period hypothesis. International Clinical Psychopharmacology 1998; 13:S31-S40.
27. McEvoy J, Hogarty G, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Archives of General Psychiatry 1991; 48:739-745.
28. Kopala L. Symptoms in neuroleptic naive first episodes schizophrenia: response to risperidone. Biological Psychiatry 1996; 39:296-298.
29. Farde E, Nordstrom A, Wissal F et al. Positron emmision tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Archives of General Psychiatry 1992; 49:533-544.
30. Kapur S, Remington G, Jones C et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. American Journal of Psychiatry 1996; 153:948-950.
31. Lehtinen V, Aaltonen J, Koffert T, Rakkolainen V, Syvalahti E. Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neurolpitisation always needed? European Psychiatry 2000; 15:312-320.
32. Cullberg J, Levander S, Holmqvist R, Mattsson M, Wieselgren I-M. One-year outcome in first episode psychosis patients in the Swedish Parachute project. Acta Psychiatrica Scandinavica 2002; 106:276-285.
33. Remington G, Kapur S, Zipursky B. Pharmacotherapy of first-episode schizphrenia. British Journal of Psychiatry 1998; 172:66-70.
34. Kapur S, Remington G. Atypical antipsychotics. Patients value the lower incidence of extrapyramidal side effects. British Medical Journal 2000; 321:1360-1361.
35. Geddes J. Prevention of relapse in schizophrenia. New England Journal of Medicine 2002; 356:56-57.
36. Falloon I, Boyd J, McGill C et al. Family management in the prevention of exacerbations of schizophrenia. New England Journal of Medicine 1982; 306:1437-1440.
37. Goldstein M, Rodrick E, Evans J, May P, Stenberg M. Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry 1978; 35:1169-1177.
38. Barraclough C, Tarrier N. Interventions with families. In: Birchwood M, Tarrier N eds. Psychological management of schizophrenia. Chichester: Wiley, 1994.
39. Schooler N. Integration of family and drug treatment strategies in the treatment of schizophrenia: a selective review. International Clinical Psychopharmacology 1995; 10:73-80.
40. Leff J, Kuipers L, Berkowitz R, Eberlein-Fries R, Sturgeon D. A controlled trial of intervention in the families of schizophrenic patients. British Journal of Psychiatry 1982; 146:594-600.
41. Pilling S, Bebbington P, Kuipers E et al. Psychological treatments in schizophrenia: 1. Meta-analysis of family intervention and cognitive behaviour therapy. Psychological Medicine 2002; 32:763-782.
42. Tarrier N, Barrowclough C, Vaughn C et al. The community management of schizophrenia: a controlled trial of a behavioural intervention with families to reduce relapse. British Journal of Psychiatry 1988; 153:532-542.
43. McGorry P. The concept of recovery and secondary prevention in psychotic disorders. Australian and New Zealand Journal of Psychiatry 1992: 26:3-17.
44. Birchwood M, Macmillan F. Early intervention in schizophrenia. Australian and New Zealand Journal of Psychiatry 1993; 27:374-378.
45. Tarrier N, Birchwood M. Making a reality of the community management of schizophrenia. In: Birchwood M, Tarrier N eds. Psychological management of schizophrenia. Chichester: Wiley, 1994.
46. Drury V, Birchwood M, Cochrane M, Macmillan F. Cognitive therapy and recovery from acute psychosis: a controlled trial. I. Impact on psychotic symptoms. II. Impact on recovery time. British Journal of Psychiatry 1996; 169:593-607.
47. Lewis S, Tarrier N, Haddock G et al. Randomised controlled trial of cognitive behaviour therapy in early schizophrenia: Acute phase outcomes. British Journal of Psychiatry 2002; 181:S91-S97.
48. McGorry P, Killackey E, Elkins K, Lamber M, Lambert T. Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia. Australasian Psychiatry 2003; 11: 136-147.
49. McGrath J, McGlashan T. Improving outcomes for recent-onset psychoses: disentangling hope, speculation and evidence. Acta Psychiatrica Scandinavica 1999; 100:83-84.
50. McGorry P, Edwards J. The feasibility and effectiveness of early intervention in psychotic disorders: the Australian experience. International Clinical Psychopharmacology 1998; 13:S47-S52.
51. Power P, Elkins K, Adlard S, Curry C, McGorry P, Harrigan S. Analysis of the initial treatment phase in first-episode psychosis. British Journal of Psychiatry 1998; 172:71-76.
52. Mihalopoulos C, McGorry P, Carter R. Is phase-specific, community-oriented treatment of early psychosis an economically viable method of improving outcome? Acta Psychiatrica Scandinavica 1999; 100:47-55.
53. McGorry P. Early psychosis reform: too fast or too slow? [Comment]. Acta Psychiatrica Scandinavica 2002; 106:249-251.
54. Gorrell J, Cornish A, Tennant C et al. An. audit of an early psychosis service: What are we doing differently? Australian and New Zealand Journal of Psychiatry 2004; 38:687-693.
55. Gorrell J, Cornish A, Miller V, Nash L, Tennant C, Rosen A. Clinician attitudes towards early psychosis intervention: the first 4 years. Acta Psychiatrica Scandinavica 2002; 106:92.
56. Tollefson G, Sanger T. Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry 1997; 154:466-474.
57. Duggan L, Fenton M, Dardennes R, El-Disily A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systemic Reviews. CD001359, 2003.
58. Csernansky J, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with achisophrenia. New England Journal of Medicine 2002; 346:16-22.
59. Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J. Differential Efficacy of Olanzapine for Deficit and Nondeficit Negative Symptoms in Schizphrenia. American Journal of Psychiatry 2000; 157:987-993.
60. Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systemic Reviews CD000440, 2000.
61. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systemic overview and meta-regression analysis. British Medical Journal 2000; 321:1371-1376.
62. Van Os J, Gilvany C, Bale R et al. To what extent does symptomatic improvement result in better outcome in psychotic illness? Psychological Medicine 1999; 29:1183-1195.
63. Lukoff D, Liberman R, Nuechterlein K. Symptom monitoring in the rehabilitation of schizophrnic patients. Schizophrenia Bulletin 1986; 12:579-593.
64. Andreason N. Negative symptoms in schizophrenia. Definition and Reliability. Archives of General Psychiatry 1982; 39:784-788.
65. Wing J, Curtis R, Beevor A. HoNOS: Health of the Nation Outcome Scales: report on research and development. London: Royal College of Psychiatrists, 1996.
66. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1977; 1:385-401.
67. Pearce C, Martin G. Predicting Suicide attempts among adolescents. Acta Psychiatrica Scandinavica 1994; 90:324-328.
68. Belmont Center for Comprehensive Treatment. Adolescent drug abuse diagnosis. Philadelphia: Belmont Center for Comprehensive Treatment, 1989.
69. Szmukler G, Burgess P, Herrman H, Benson A, Colusa S, Bloch S. Caring for relatives with serious mental illness. the development of the Experience of Caregiving Inventory. Social Psychiatry and Psychiatric Epidemiology 1996; 31:137-148.
70. Rosen A, Hadzi-Pavlovic D, Parker G. The Life Skills Profile: a measure assessing function and disability in schizophrenia. Schizophrenia Bulletin 1989; 15:325-337.
71. Roggeri M. The development and use of the Verona Expectations for Care Scale (VECS) and the Verona Service Satisfaction Scale (VSSS) for measuring expectations and satisfaction with community-based psychiatric services in patients, relatives and professionals. Psychological Medicine 1993; 23:511-523.